Early-_NN and_CC Intermediate-Stage_NP Variants_NP of_IN Simian_NP Immunodeficiency_NN Virus_NP Replicate_NP Efficiently_NP in_IN Cells_NP Lacking_NP CCR5_NP Primate_NP lentiviruses_NNS are_VBP thought_VBN to_TO use_VB the_DT chemokine_NN receptor_NN CCR5_NP as_IN the_DT major_JJ coreceptor_NN for_IN entry_NN into_IN cells_NNS ._SENT Here_RB we_PP show_VBP that_IN some_DT variants_NNS of_IN simian_JJ immunodeficiency_NN virus_NN (_( SIV_NP )_) replicate_VB efficiently_RB in_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMCs_NP )_) lacking_VBG a_DT functional_JJ CCR5_NP ._SENT There_EX were_VBD differences_NNS in_IN the_DT replication_NN patterns_NNS of_IN sequential_JJ variants_NNS that_WDT evolved_VBD during_IN SIVMne_NP infection_NN ;_: the_DT late-stage_NN pathogenic_JJ variants_NNS were_VBD unable_JJ to_TO replicate_VB in_IN PBMCs_NNS lacking_VBG CCR5_NP ,_, whereas_IN the_DT early-_NN and_CC intermediate-stage_NN viruses_NNS replicated_VBN as_RB well_RB in_IN PBMCs_NNS lacking_VBG CCR5_NP as_IN they_PP did_VBD in_IN cells_NNS with_IN wild-type_NN CCR5_NP ._SENT The_DT coreceptor_NN specificities_NNS of_IN these_DT sequential_JJ variants_NNS were_VBD compared_VBN using_VBG indicator_NN cell_NN lines_NNS expressing_VBG known_JJ SIV_NP coreceptors_NNS ._SENT Among_IN the_DT known_JJ SIV_NP coreceptors_NNS ,_, there_EX were_VBD none_NN that_WDT were_VBD functional_JJ for_IN the_DT early_JJ and_CC intermediate_JJ variants_NNS but_CC not_RB the_DT late-stage_NN variants_NNS ,_, suggesting_VBG that_IN the_DT coreceptor_NN used_VBN for_IN replication_NN in_IN PBMCs_NP may_MD be_VB a_DT coreceptor_NN that_WDT has_VBZ not_RB yet_RB been_VBN described_VBN ._SENT Because_IN some_DT variants_NNS replicate_VBP with_IN high_JJ efficiency_NN in_IN peripheral_JJ blood_NN cells_NNS using_VBG this_DT as_RB yet_RB uncharacterized_VBN cellular_JJ receptor_NN ,_, this_DT coreceptor_NN may_MD be_VB important_JJ for_IN viral_JJ entry_NN of_IN some_DT target_NN cell_NN populations_NNS in_IN the_DT host_NN ._SENT The_DT entry_NN of_IN primate_NN lentiviruses_NNS into_IN cells_NNS involves_VBZ a_DT series_NN of_IN interactions_NNS with_IN host_NN cell_NN receptors_NNS ,_, starting_VBG with_IN binding_VBG of_IN the_DT viral_JJ envelope_NN to_TO the_DT CD4_NP protein_NN ;_: this_DT leads_NNS to_TO a_DT conformational_JJ change_NN that_WDT allows_VBZ binding_JJ of_IN the_DT envelope_NN protein_NN to_TO a_DT second_JJ receptor_NN ._SENT This_DT coreceptor_NN can_MD be_VB one_CD of_IN a_DT variety_NN of_IN seven_CD transmembrane-spanning_NN G-protein-coupled_JJ chemokine_NN receptors_NNS ._SENT The_DT chemokine_NN receptor_NN CCR5_NP is_VBZ used_VBN by_IN most_JJS isolates_NNS of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) and_CC is_VBZ thought_VBN to_TO be_VB the_DT coreceptor_NN that_WDT is_VBZ expressed_VBN on_IN cells_NNS that_WDT are_VBP the_DT earliest_JJS targets_NNS for_IN virus_NN replication_NN after_IN transmission_NN ._SENT Some_DT later-stage_NN isolates_VBZ of_IN HIV-1_JJ use_NN CXCR4_NN as_IN a_DT coreceptor_NN ,_, and_CC many_JJ of_IN these_DT variants_NNS also_RB retain_VBP the_DT ability_NN to_TO use_VB CCR5_NP as_IN a_DT coreceptor_NN ,_, perhaps_RB allowing_VBG some_DT flexibility_NN for_IN later-stage_NN viruses_NNS to_TO infect_VB a_DT wider_JJR range_NN of_IN target_NN cells_NNS ._SENT A_DT minority_NN of_IN HIV-1_JJ variants_NNS can_MD use_VB other_JJ G-protein-coupled_JJ receptors_NNS for_IN entry_NN ,_, although_IN the_DT efficiency_NN of_IN infection_NN is_VBZ reduced_VBN relative_JJ to_TO that_DT for_IN CCR5-mediated_JJ entry_NN ,_, and_CC the_DT importance_NN of_IN these_DT alternate_JJ coreceptors_NNS in_IN infection_NN is_VBZ unclear_JJ (_( reviewed_VBN in_IN references_NNS ,_, ,_, and_CC )_) ._SENT Simian_JJ immunodeficiency_NN virus_NN (_( SIV_NP )_) also_RB uses_VBZ CCR5_NP as_IN a_DT coreceptor_NN ._SENT In_IN addition_NN ,_, several_JJ other_JJ cellular_JJ receptors_NNS can_MD function_VB as_IN coreceptors_NNS for_IN SIV_NP ,_, including_VBG GPR1_NP ,_, GPR15_NP ,_, CCR8_NP ,_, APJ_NP ,_, STRL33_NP ,_, and_CC CHEMR23_NP (_( ,_, ,_, ,_, ,_, ;_: G._NP Alkhatib_NP ,_, F._NP Liao_NP ,_, E._NP A._NP Berger_NP ,_, J._NP M._NP Farber_NP ,_, and_CC K._NP W._NP C._NP Peden_NP ,_, Letter_NP ,_, Nature_NP 388:238_CD ,_, 1997_CD )_) ._SENT Many_JJ pathogenic_JJ SIVs_NNS can_MD efficiently_RB infect_VB cells_NNS by_IN using_VBG both_DT CCR5_NP and_CC GPR15_NP as_IN a_DT coreceptor_NN with_IN CD4_NP ._SENT However_RB ,_, studies_NNS of_IN SIV_NP infection_NN of_IN macaques_NNS suggest_VBP that_IN GPR15_NP may_MD not_RB be_VB important_JJ for_IN virus_NN replication_NN in_IN vivo_JJ because_IN mutations_NNS that_WDT abolish_VBP GPR15-mediated_JJ entry_NN of_IN SIVmac239_NP did_VBD not_RB affect_VB the_DT levels_NNS of_IN virus_NN in_IN the_DT infected_JJ animal_NN ._SENT In_IN general_JJ ,_, it_PP remains_VBZ unclear_JJ if_IN coreceptors_NNS other_JJ than_IN CCR5_NP play_VBP a_DT major_JJ role_NN in_IN SIV_NP or_CC HIV_NP replication_NN at_IN any_DT stage_NN of_IN infection_NN and_CC disease_NN in_IN the_DT host_NN ._SENT Previous_JJ studies_NNS of_IN SIV_NP infection_NN of_IN Macaca_NP nemestrina_NP demonstrated_VBD that_IN the_DT late-stage_NN variants_NNS are_VBP more_RBR pathogenic_JJ than_IN the_DT cloned_VBN infecting_VBG virus_NN ,_, SIVMneCL8_NP ,_, from_IN which_WDT they_PP arose_VBD in_IN the_DT host_NN ._SENT Viruses_NNS that_WDT evolved_VBD at_IN intermediate_JJ (_( 35-week-postinfection_JJ )_) and_CC late_JJ (_( 170-week-postinfection_JJ )_) stages_NNS in_IN animals_NNS infected_VBN with_IN SIVMneCL8_NP replicated_VBD 100-_CD and_CC 3,000-fold_JJ better_JJR ,_, respectively_RB ,_, than_IN the_DT parental_JJ viral_JJ clone_NN when_WRB transmitted_VBN to_TO naive_JJ monkeys_NNS ._SENT Some_DT of_IN the_DT increased_VBN replication_NN was_VBD attributable_JJ to_TO the_DT inability_NN of_IN these_DT intermediate-_NN and_CC late-stage_NN viruses_NNS to_TO elicit_VB neutralizing_VBG antibody_NN responses_NNS ._SENT However_RB ,_, because_IN neither_CC the_DT intermediate_JJ nor_CC the_DT late_JJ viruses_NNS could_MD elicit_VB detectable_JJ neutralizing_VBG antibodies_NNS ,_, the_DT similar30-fold-higher_NN replication_NN of_IN the_DT two_CD viruses_NNS may_MD reflect_VB an_DT additional_JJ selective_JJ advantage_NN of_IN the_DT late-stage_NN variant_NN ._SENT In_IN our_PP$ initial_JJ studies_NNS of_IN the_DT coreceptor_NN specificities_NNS of_IN these_DT different_JJ SIVMne_NP variants_NNS ,_, we_PP found_VBD no_DT differences_NNS in_IN the_DT coreceptor_NN preferences_NNS of_IN these_DT viruses_NNS ;_: all_RB of_IN the_DT SIVMne_NP variants_NNS tested_VBD were_VBD able_JJ to_TO infect_VB cells_NNS in_IN culture_NN by_IN using_VBG either_DT CCR5_NP or_CC GPR15_NP ,_, but_CC not_RB CXCR4_NP ._SENT To_TO examine_VB if_IN coreceptors_NNS other_JJ than_IN CCR5_NP were_VBD important_JJ for_IN replication_NN of_IN these_DT variants_NNS in_IN relevant_JJ cell_NN types_NNS such_JJ as_IN T_NN lymphocytes_NNS and_CC macrophages_NNS ,_, we_PP examined_VBD the_DT ability_NN of_IN the_DT viruses_NNS to_TO infect_VB human_JJ peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMCs_NP )_) from_IN donors_NNS who_WP were_VBD homozygous_JJ for_IN a_DT 32-bp_JJ deletion_NN of_IN CCR5_NP (_( Delta32_NP PBMCs_NP )_) ._SENT The_DT viruses_NNS examined_VBD were_VBD chimeric_JJ viruses_NNS encoding_VBG envelope_NN surface_NN unit_NN proteins_NNS that_WDT were_VBD obtained_VBN from_IN intermediate_NN [_SYM 35-week-postinfection_JJ ;_: SIVMneCL8(35wkSU)_NP ]_SYM and_CC late_RB [_SYM 170-week-postinfection_NN ;_: SIVMneCL8(170wkSU)_NP ]_SYM stages_VBZ of_IN infection_NN in_IN animals_NNS inoculated_VBN with_IN SIVMneCL8_NP ._SENT Thus_RB ,_, the_DT only_JJ difference_NN between_IN viruses_NNS was_VBD in_IN the_DT envelope_NN surface_NN protein_NN ._SENT Blood_NN samples_NNS from_IN four_CD HIV-1-seronegative_JJ donors_NNS ,_, two_CD with_IN a_DT wild-type_JJ CCR5_NP allele_NN (_( 35-9_CD and_CC 53-5_CD )_) and_CC two_CD with_IN the_DT homozygous_JJ Delta32_NP allele_NN (_( 07-5_CD and_CC 43-1_CD )_) ,_, were_VBD provided_VBN without_IN indication_NN of_IN the_DT CCR5_NP status_NN ._SENT PBMCs_NNS were_VBD isolated_VBN from_IN whole_JJ blood_NN by_IN Ficoll-Hypaque_NP centrifugation_NN and_CC cultured_VBN by_IN methods_NNS similar_JJ to_TO those_DT described_VBN previously_RB ._SENT SIV_NP particles_NNS were_VBD made_VBN by_IN transfecting_VBG 293T_JJ cells_NNS with_IN the_DT proviral_JJ clones_NNS and_CC then_RB passaging_VBG cell-free_JJ virus_NN harvested_VBN 2_CD days_NNS later_RBR for_IN 1_CD to_TO 2_CD weeks_NNS in_IN CEMx174_NP cells_NNS ._SENT The_DT infectious_JJ titer_NN was_VBD determined_VBN using_VBG sMAGI_NN cells_NNS ._SENT SIVmac239_NP and_CC the_DT SIV/HIV-1_NP chimera_NN SHIV162_NP were_VBD also_RB generated_VBN in_IN CEMx174_NP cells_NNS ;_: in_IN the_DT case_NN of_IN SHIV162_NP ,_, the_DT virus_NN titer_NN was_VBD determined_VBN using_VBG MAGI-CCR5_JJ cells_NNS ._SENT Phytohemagglutinin_NP (PHA)-stimulated_VBD PBMCs_NP were_VBD infected_VBN with_IN each_DT virus_NN at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 0.01_CD ._SENT Every_DT 2_CD to_TO 3_CD days_NNS ,_, medium_NN was_VBD replaced_VBN ,_, and_CC the_DT level_NN of_IN virus_NN replication_NN was_VBD assessed_VBN by_IN assaying_VBG the_DT filtered_VBN supernatant_JJ for_IN SIV_NP p27gag_NN ._SENT The_DT results_NNS of_IN the_DT first_JJ infection_NN study_NN are_VBP shown_VBN in_IN Fig._NN ,_, and_CC they_PP represent_VBP the_DT averages_NNS of_IN results_NNS from_IN duplicate_JJ infections_NNS ._SENT SHIV162_NP was_VBD used_VBN as_IN a_DT control_NN for_IN these_DT experiments_NNS because_IN it_PP is_VBZ dependent_JJ on_IN CCR5_NP for_IN entry_NN and_CC thus_RB would_MD not_RB be_VB expected_VBN to_TO replicate_VB in_IN PBMCs_NNS lacking_VBG a_DT functional_JJ CCR5_NP protein_NN ._SENT As_IN expected_VBN ,_, SHIV162_NP replicated_VBD to_TO high_JJ levels_NNS in_IN the_DT PBMCs_NP from_IN two_CD donors_NNS and_CC not_RB in_IN the_DT PBMCs_NP from_IN two_CD others_NNS ._SENT Upon_IN unblinding_NN of_IN the_DT experiment_NN ,_, the_DT donors_NNS were_VBD shown_VBN to_TO have_VB the_DT expected_VBN CCR5_NP genotype_NN ._SENT SHIV162_NP replicated_VBD to_TO high_JJ levels_NNS in_IN PBMCs_NP from_IN each_DT of_IN the_DT wild-type_JJ CCR5_NP donors_NNS ,_, with_IN peak_NN levels_NNS of_IN p27gag_NN production_NN of_IN similar19_NN to_TO 58_CD ng/ml_NNS (_( Fig._NN ;_: Table_NP )_) ._SENT Somewhat_RB lower_JJR peak_NN levels_NNS of_IN replication_NN (_( similar6_NN to_TO 15_CD ng/ml_NNS )_) were_VBD observed_VBN for_IN each_DT of_IN the_DT SIVs_NP tested_VBD in_IN PBMCs_NP from_IN the_DT two_CD donors_NNS with_IN a_DT wild-type_JJ CCR5_NP allele_NN ._SENT In_IN PBMCs_NNS from_IN donors_NNS with_IN a_DT deletion_NN in_IN CCR5_NP ,_, the_DT infection_NN profile_NN of_IN SIVMne170SU_NP followed_VBD a_DT similar_JJ pattern_NN as_IN that_WDT observed_VBD with_IN the_DT CCR5-dependent_NP SHIV162_NP control_NN virus_NN ;_: there_EX was_VBD a_DT low_JJ level_NN of_IN virus_NN replication_NN (_( peak_NN of_IN <=0.6_JJ ng_NNS of_IN p27gag/ml_NN )_) of_IN the_DT chimera_NN carrying_VBG the_DT envelope_NN gene_NN from_IN late-stage_NN infection_NN ._SENT Surprisingly_RB ,_, the_DT parental_JJ ,_, early-stage_NN SIVMne_NP clone_NN ,_, SIVMneCL8_NP ,_, replicated_VBN to_TO high_JJ levels_NNS in_IN the_DT cells_NNS lacking_VBG CCR5_NP ._SENT Similarly_RB ,_, the_DT virus_NN carrying_VBG the_DT prototype_NN envelope_NN gene_NN from_IN intermediate_JJ stages_NNS of_IN infection_NN also_RB replicated_VBN in_IN PBMCs_NNS lacking_VBG CCR5_NP ._SENT In_IN both_DT cases_NNS ,_, the_DT replication_NN kinetics_NN of_IN these_DT early-_NN and/or_CC intermediate-stage_NN viruses_NNS were_VBD very_RB similar_JJ in_IN PBMCs_NP from_IN wild-type_NP and_CC Delta32_NP CCR5_NP donors_NNS ._SENT The_DT infection_NN experiments_NNS were_VBD repeated_VBN on_IN a_DT second_JJ occasion_NN ,_, and_CC similar_JJ results_NNS were_VBD obtained_VBN ._SENT Table_NN shows_VBZ the_DT peak_JJ viral_JJ levels_NNS observed_VBN in_IN both_DT infection_NN experiments_NNS in_IN which_WDT we_PP used_VBD PBMCs_NNS from_IN the_DT same_JJ four_CD donors_NNS ,_, two_CD with_IN wild-type_NP CCR5_NP and_CC two_CD with_IN Delta32_NP CCR5_NP ._SENT In_IN summary_NN ,_, the_DT control_NN virus_NN SHIV162_NN replicated_VBN to_TO similar100-fold-higher_NN peak_NN levels_NNS in_IN each_DT of_IN the_DT four_CD experiments_NNS with_IN PBMCs_NP carrying_VBG a_DT wild-type_JJ CCR5_NP gene_NN than_IN in_IN experiments_NNS with_IN PBMCs_NNS carrying_VBG Delta32_NP CCR5_NP ._SENT A_DT similar_JJ difference_NN (_( 10-_CD to_TO 100-fold_NN )_) between_IN peak_NN levels_NNS of_IN p27gag_NN in_IN Delta32_NP PBMCs_NP and_CC those_DT in_IN wild-type_NP PBMCs_NP was_VBD observed_VBN for_IN both_CC the_DT full-length_JJ proviral_JJ clone_NN from_IN 170_CD weeks_NNS postinfection_NN ,_, SIVMne170_NP ,_, and_CC the_DT chimera_NN encoding_VBG the_DT envelope_NN from_IN this_DT provirus_NN ,_, SIVMneCL8(170wkSU_NP )_) ._SENT In_IN contrast_NN ,_, both_CC SIVMneCL8_NP and_CC SIVMneCL8(35wkSU)_NP replicated_VBD to_TO similar_JJ levels_NNS in_IN PBMCs_NP from_IN wild-type_NP and_CC Delta32_NP CCR5_NP donors_NNS (_( approximately_RB one-_JJ to_TO threefold_JJ differences_NNS in_IN peak_JJ viral_JJ levels_NNS )_) ._SENT In_IN the_DT second_JJ experiment_NN ,_, SIVmac239_NP was_VBD also_RB examined_VBN because_IN previous_JJ studies_NNS have_VBP shown_VBN that_IN this_DT virus_NN can_MD replicate_VB in_IN PBMCs_NNS lacking_VBG CCR5_NP from_IN some_DT donors_NNS but_CC not_RB others_NNS ._SENT Replication_NN of_IN SIVmac239_NP was_VBD only_RB three-_NNS to_TO fourfold_RB lower_JJR in_IN Delta32_NP CCR5_NP PBMCs_NP ;_: the_DT replication_NN pattern_NN was_VBD very_RB similar_JJ to_TO that_DT of_IN the_DT intermediate-stage_JJ SIVMne_NP variant_NN in_IN the_DT second_JJ experiment_NN ,_, where_WRB it_PP was_VBD tested_VBN in_IN parallel_NN ._SENT Thus_RB ,_, the_DT major_JJ novel_NN finding_NN is_VBZ that_IN the_DT early-_NN and_CC intermediate-stage_JJ SIVMne_NP variants_NNS can_MD replicate_VB in_IN PBMCs_NP in_IN the_DT absence_NN of_IN CCR5_NP ,_, whereas_IN late-stage_NN SIVMne_NP variants_NNS are_VBP much_RB more_JJR CCR5_NP dependent_NN ._SENT To_TO determine_VB whether_IN the_DT coreceptor_NN that_WDT is_VBZ used_VBN by_IN early-_NN and_CC intermediate-stage_JJ SIVMne_NP variants_NNS is_VBZ among_IN those_DT that_WDT have_VBP been_VBN described_VBN ,_, we_PP examined_VBD the_DT ability_NN of_IN the_DT viral_JJ variants_NNS to_TO infect_VB a_DT set_NN of_IN HOS-CD4+_NP (_( GHOST_NP )_) cell_NN lines_NNS that_WDT express_VBP various_JJ coreceptors_NNS known_VBN to_TO support_VB infection_NN by_IN different_JJ strains_NNS of_IN SIV_NP ._SENT It_PP was_VBD previously_RB shown_VBN that_IN all_DT SIVMne_NP variants_NNS use_VBP CCR5_NP and_CC GPR15_NP for_IN entry_NN into_IN target_NN cells_NNS ._SENT None_NN of_IN the_DT SIVMne_NP variants_NNS was_VBD able_JJ to_TO use_VB STRL33_NP (_( now_RB called_VBN CXCR6_NP )_) or_CC CXCR4_NP as_IN a_DT coreceptor_NN for_IN entry_NN ,_, at_IN least_JJS at_IN the_DT levels_NNS expressed_VBN on_IN GHOST_NP cells_NNS that_WDT permit_VBP HIV-1_JJ infection_NN ._SENT To_TO examine_VB other_JJ potential_JJ coreceptors_NNS ,_, we_PP infected_VBD a_DT panel_NN of_IN GHOST4_NP cells_NNS expressing_VBG the_DT following_VBG coreceptors_NNS :_: CCR8_NP ,_, GPR1_NP ,_, APJ_NP ,_, and_CC CHEMR23_NP ._SENT We_PP compared_VBD infection_NN of_IN these_DT cells_NNS with_IN infection_NN of_IN GHOST_NP cells_NNS expressing_VBG CCR5_NP (_( GHOST_NP cells_NNS expressing_VBG CCR8_NP ,_, GPR1_NP ,_, and_CC CCR5_NP were_VBD kindly_RB provided_VBN by_IN Dan_NP Littman_NP )_) ._SENT In_IN the_DT case_NN of_IN APJ_NP and_CC CHEMR23_NP ,_, the_DT cells_NNS were_VBD constructed_VBN by_IN transducing_VBG the_DT parental_JJ indicator_NN cells_NNS (_( GHOST4_NP )_) ,_, which_WDT are_VBP HOS_JJ cells_NNS modified_VBN to_TO stably_RB express_VB the_DT human_JJ CD4_NP gene_NN and_CC humanized_VBD green_JJ fluorescent_JJ protein_NN (_( GFP_NP )_) under_IN the_DT control_NN of_IN the_DT HIV-2_NP long_JJ terminal_NN repeat_NN ,_, with_IN retroviral_JJ particles_NNS carrying_VBG a_DT pBabe-puromycin_NN vector_NN containing_VBG the_DT coreceptor_NN gene_NN of_IN interest_NN (_( APJ_NP or_CC CHEMR23_NP )_) ._SENT The_DT results_NNS of_IN infection_NN of_IN GHOST_NP cells_NNS expressing_VBG various_JJ coreceptors_NNS with_IN the_DT different_JJ SIVMne_NP variants_NNS and_CC relevant_JJ control_NN viruses_NNS are_VBP shown_VBN in_IN Table_NP ._SENT As_IN expected_VBN ,_, all_DT viruses_NNS tested_VBN were_VBD able_JJ to_TO use_VB CCR5_NP ._SENT However_RB ,_, neither_CC the_DT early-stage_NN variant_JJ SIVMneCL8_NP nor_CC the_DT intermediate-stage_NN variant_NN SIVMneCL8(35wkSU)_NP was_VBD able_JJ to_TO use_VB any_DT of_IN these_DT additional_JJ coreceptors_NNS ._SENT The_DT late-stage_NN variant_NN SIVMneCL8(170wkSU)_NP was_VBD able_JJ to_TO use_VB CCR8_NP and_CC GPR1_NP in_IN addition_NN to_TO CCR5_NP and_CC GPR15_NP ,_, although_IN the_DT efficiency_NN of_IN alternative_JJ coreceptor_NN usage_NN was_VBD reduced_VBN compared_VBN to_TO CCR5_NP usage_NN ._SENT The_DT results_NNS of_IN these_DT studies_NNS suggest_VBP that_IN some_DT SIV_NP variants_NNS can_MD replicate_VB to_TO high_JJ levels_NNS in_IN PBMCs_NNS lacking_VBG CCR5_NP ._SENT To_TO our_PP$ surprise_NN ,_, this_DT was_VBD true_JJ for_IN early-_NN and_CC intermediate-stage_NN variants_NNS but_CC not_RB for_IN later-stage_NN variants_NNS that_WDT evolved_VBD from_IN them_PP ._SENT This_DT result_NN was_VBD unexpected_JJ because_IN the_DT late-stage_NN virus_NN SIVMne170_NP replicated_VBD to_TO much_RB higher_JJR levels_NNS in_IN the_DT animal_NN ,_, as_RB judged_VBN by_IN both_DT plasma_NN and_CC lymph_NN node_NN viral_JJ RNA_NP levels_NNS ,_, and_CC the_DT late-stage_NN virus_NN was_VBD more_RBR pathogenic_JJ ._SENT This_DT suggests_VBZ that_IN the_DT alternative_JJ coreceptor_NN used_VBN by_IN early-stage_NN viruses_NNS may_MD not_RB be_VB important_JJ for_IN high_JJ levels_NNS of_IN virus_NN replication_NN per_IN se_FW ._SENT Thus_RB ,_, entry_NN with_IN the_DT use_NN of_IN this_DT coreceptor_NN ,_, if_IN relevant_JJ in_IN vivo_JJ ,_, may_MD be_VB for_IN a_DT select_JJ subset_NN of_IN targets_NNS ,_, perhaps_RB cells_NNS important_JJ early_RB in_IN infection_NN and/or_CC with_IN viruses_NNS that_WDT cause_VBP a_DT more_RBR prolonged_JJ disease_NN course_NN ._SENT Additional_JJ studies_NNS with_IN sequential_JJ viruses_NNS from_IN monkeys_NNS infected_VBN with_IN other_JJ SIV_NP or_CC simian/human_NP immunodeficiency_NN virus_NN (_( SHIV_NP )_) strains_NNS may_MD provide_VB insights_NNS as_IN to_TO whether_IN there_EX is_VBZ a_DT relationship_NN between_IN CCR5-independent_JJ replication_NN and_CC stage_NN of_IN infection_NN for_IN primate_NN lentiviruses_NNS ._SENT One_PP might_MD assume_VB that_IN the_DT opposite_NN is_VBZ the_DT case_NN for_IN HIV-1_JJ infection_NN in_IN humans_NNS ,_, because_IN in_IN some_DT individuals_NNS ,_, the_DT late-stage_NN HIV-1_JJ variants_NNS acquire_VB the_DT ability_NN to_TO use_VB the_DT CXCR4_NP coreceptor_NN to_TO infect_VB PBMCs_NNS ._SENT However_RB ,_, there_EX is_VBZ no_DT evidence_NN that_IN well-characterized_JJ sequential_JJ variants_NNS from_IN the_DT same_JJ source_NN have_VBP been_VBN tested_VBN for_IN replication_NN in_IN PBMCs_NNS that_WDT lack_VBP CCR5_NP ._SENT Both_DT GPR15_NP and_CC STRL33_NP are_VBP expressed_VBN on_IN activated_VBN PBMCs_NNS (_( -_: ,_, )_) ._SENT However_RB ,_, there_EX was_VBD not_RB a_DT correlation_NN between_IN the_DT use_NN of_IN these_DT coreceptors_NNS and_CC the_DT ability_NN of_IN the_DT SIV_NP variant_NN tested_VBD to_TO replicate_VB in_IN PBMCs_NNS lacking_VBG CCR5_NP ._SENT The_DT coreceptors_NNS tested_VBN were_VBD of_IN human_JJ origin_NN ,_, so_IN species-specific_JJ differences_NNS in_IN the_DT GHOST_NP cell_NN and_CC the_DT PBMC_NP experiments_NNS cannot_MD account_VB for_IN the_DT findings_NNS ._SENT None_NN of_IN the_DT SIVMne_NP variants_NNS efficiently_RB infect_VBP GHOST_NP cells_NNS expressing_VBG STRL33_NP ,_, whereas_IN GPR15_NP is_VBZ used_VBN by_IN all_DT of_IN the_DT SIVs_NP tested_VBD ,_, including_VBG the_DT late-stage_NN variants_NNS ;_: thus_RB ,_, infection_NN via_IN one_CD of_IN these_DT coreceptors_NNS would_MD not_RB appear_VB to_TO explain_VB the_DT observed_JJ differences_NNS in_IN replication_NN of_IN the_DT SIV_NP variants_NNS in_IN Delta32_NP PBMCs_NP ._SENT However_RB ,_, we_PP cannot_MD completely_RB rule_VB out_RP that_IN the_DT differences_NNS we_PP observed_VBD between_IN viruses_NNS reflect_VBP a_DT difference_NN between_IN their_PP$ abilities_NNS to_TO use_VB a_DT given_VBN coreceptor_NN when_WRB expressed_VBN on_IN PBMCs_NP and_CC those_DT when_RB expressed_VBN on_IN GHOST_NP cells_NNS ._SENT This_DT could_MD occur_VB if_IN PBMCs_NP express_VBP much_RB higher_JJR levels_NNS of_IN the_DT coreceptor_NN in_IN question_NN than_IN do_VB the_DT GHOST_NP cell_NN lines_NNS ,_, because_IN it_PP has_VBZ been_VBN noted_VBN that_IN ,_, for_IN some_DT coreceptors_NNS such_JJ as_IN STRL33_NP ,_, the_DT levels_NNS of_IN expression_NN have_VBP a_DT major_JJ impact_NN on_IN viral_JJ replication_NN ._SENT Thus_RB ,_, we_PP cannot_MD rule_VB out_RP that_DT early-_NN and_CC late-stage_NN variants_NNS differ_VBP in_IN their_PP$ abilities_NNS to_TO infect_VB PBMCs_NP via_IN STRL33_NP ._SENT Coreceptor-independent_JJ entry_NN is_VBZ not_RB a_DT likely_JJ explanation_NN for_IN these_DT findings_NNS because_IN these_DT SIVs_NP are_VBP dependent_JJ on_IN a_DT coreceptor_NN for_IN entry_NN ;_: SIVMneCL8_NP did_VBD not_RB infect_VB HeLa_NP cells_NNS expressing_VBG CD4_NP alone_RB ,_, but_CC it_PP could_MD infect_VB HeLa_NP cells_NNS expressing_VBG CD4_NP and_CC CCR5_NP ._SENT In_IN GHOST_NP cells_NNS ,_, we_PP did_VBD observe_VB low-level_JJ infection_NN of_IN the_DT late-stage_NN variants_NNS with_IN various_JJ alternative_JJ coreceptors_NNS such_JJ as_IN CCR8_NP and_CC GPR1_NP ,_, suggesting_VBG that_IN the_DT late-stage_NN viruses_NNS may_MD have_VB more_JJR flexibility_NN in_IN the_DT coreceptors_NNS that_WDT they_PP use_VBP for_IN entry_NN ._SENT However_RB ,_, we_PP found_VBD no_DT evidence_NN that_IN a_DT known_JJ SIV_NP coreceptor_NN can_MD be_VB used_VBN for_IN entry_NN by_IN the_DT early-_NN and_CC intermediate-stage_JJ SIVMne_NP variants_NNS ,_, but_CC not_RB the_DT late-stage_NN variant_NN ._SENT There_EX were_VBD no_DT coreceptors_NNS that_WDT distinguished_VBD SIVmac239_NP from_IN the_DT early-_NN and/or_CC intermediate-stage_JJ SIVMne_NP variants_NNS ,_, and_CC previous_JJ results_NNS ,_, which_WDT were_VBD confirmed_VBN here_RB ,_, indicate_VBP that_IN SIVmac239_NP can_MD infect_VB PBMCs_NNS from_IN some_DT donors_NNS lacking_VBG CCR5_NP ._SENT The_DT earlier_JJR studies_NNS by_IN Zhang_NP et_FW al._FW ,_, which_WDT included_VBD studies_NNS with_IN inhibitor_NN molecules_NNS that_WDT block_VBP CCR5_JJ entry_NN ,_, suggested_VBD that_IN a_DT coreceptor_NN other_JJ than_IN CCR5_NP may_MD be_VB used_VBN by_IN SIVmac239_NP for_IN replication_NN in_IN PBMCs_NP ,_, although_IN the_DT specific_JJ coreceptor_NN could_MD not_RB be_VB identified_VBN ._SENT Our_PP$ studies_NNS indicate_VBP that_IN the_DT same_JJ is_VBZ true_JJ for_IN some_DT variants_NNS of_IN SIVMne_NP ._SENT Collectively_RB ,_, these_DT studies_NNS suggest_VBP that_IN the_DT coreceptor_NN that_WDT facilitates_VBZ high-level_JJ replication_NN of_IN some_DT SIVs_NP in_IN PBMCs_NP lacking_VBG CCR5_NP may_MD be_VB a_DT protein_NN that_WDT has_VBZ not_RB yet_RB been_VBN identified_VBN as_IN a_DT coreceptor_NN for_IN primate_NN lentiviruses_NNS ._SENT Because_IN this_DT coreceptor_NN permits_VBZ entry_NN in_IN peripheral_JJ blood_NN cells_NNS ,_, this_DT suggests_VBZ that_IN the_DT as_RB yet_RB unidentified_JJ coreceptor_NN may_MD be_VB important_JJ for_IN replication_NN in_IN relevant_JJ cell_NN types_NNS ._SENT Levels_NNS of_IN virus_NN production_NN ,_, as_RB measured_VBN by_IN p27gag_NN antigen_NN capture_NN assay_NN ,_, in_IN PBMCs_NNS infected_VBN with_IN SIV_NP and_CC SHIV_NP ._SENT Levels_NNS of_IN virus_NN production_NN ,_, as_RB measured_VBN by_IN p27gag_NN antigen_NN capture_NN assay_NN ,_, in_IN PBMCs_NNS infected_VBN with_IN SIV_NP and_CC SHIV_NP ._SENT For_IN these_DT experiments_NNS ,_, PBMCs_NP were_VBD isolated_VBN from_IN the_DT whole_JJ blood_NN of_IN four_CD HIV-1-seronegative_JJ donors_NNS ,_, two_CD with_IN wild-type_NN CCR5_NP (_( ,_, 53-3_CD ;_: ,_, 35-9_CD )_) and_CC two_CD with_IN CCR5_NP with_IN a_DT 32-bp-deletion_JJ (_( *_SYM ,_, 43-1_CD ;_: ,_, 07-5_CD )_) ._SENT After_IN Ficoll-Hypaque_NP centrifugation_NN ,_, the_DT cells_NNS were_VBD cultured_VBN with_IN 1_CD mug_NN of_IN PHA/ml_NP in_IN RPMI_NP 1640_CD supplemented_VBD with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( RPMI_NP complete_VB )_) and_CC 10_CD U_NN of_IN human_JJ recombinant_JJ interleukin-2/ml_NN for_IN 3_CD days_NNS ._SENT The_DT cells_NNS were_VBD pelleted_VBN by_IN centrifugation_NN at_IN 300_CD x_NN g_NN ,_, washed_VBN with_IN RPMI_NP complete_JJ to_TO remove_VB the_DT PHA_NP ,_, and_CC cultured_VBN for_IN an_DT additional_JJ 24_CD h_NN in_IN RPMI_NP complete_JJ with_IN interleukin-2_NN ._SENT Duplicate_JJ cultures_NNS of_IN 2_CD x_SYM 106_CD cells/ml_NN were_VBD infected_VBN with_IN each_DT virus_NN at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 0.01_CD in_IN 1_CD ml_NN of_IN RPMI_NP complete_JJ plus_CC 10_CD U_NN of_IN interleukin-2/ml_NN ._SENT The_DT infectious_JJ titers_NNS of_IN the_DT viruses_NNS were_VBD determined_VBN by_IN sMAGI_NN assay_NN for_IN SIV_NP or_CC MAGI-CCR5_NP assay_NN for_IN SHIV162_NP ._SENT Fourteen_NN hours_NNS later_RBR ,_, the_DT cells_NNS were_VBD pelleted_VBN at_IN 300_CD x_NN g_NN ,_, washed_VBD three_CD times_NNS with_IN RPMI_NP complete_JJ to_TO remove_VB any_DT residual_JJ cell-free_JJ virions_NNS ,_, and_CC resuspended_VBD in_IN 5_CD ml_NN of_IN RPMI_NP complete_JJ plus_CC interleukin-2_JJ (_( 10_CD U/ml_NN )_) ._SENT Every_DT 2_CD to_TO 3_CD days_NNS ,_, 2_CD ml_NN of_IN cell-free_JJ supernatant_JJ was_VBD removed_VBN and_CC replaced_VBN with_IN fresh_JJ RPMI_NP complete_JJ supplemented_VBD with_IN 10_CD U_NN of_IN interleukin-2/ml_NN ._SENT Cell-free_RB supernatant_JJ that_WDT was_VBD collected_VBN was_VBD stored_VBN at_IN -80C_NN and_CC used_VBN to_TO monitor_VB viral_JJ replication_NN by_IN assaying_VBG for_IN p27gag_NN antigen_NN with_IN an_DT enzyme-linked_JJ immunosorbent_JJ assay_NN kit_NN (_( Coulter_NP )_) ._SENT Peak_JJ p27gag_NN levels_NNS in_IN PBMCs_NNS infected_VBN with_IN different_JJ SIVs_NP and_CC SHIV_NP Infection_NP of_IN GHOST4_NP indicator_NN cells_NNS with_IN variants_NNS of_IN SIVMne_NP 